Participated · Series C · Apr 2026

Adcendo is advancing a pipeline of first- and potential best-in-class antibody-drug conjugates, integrating novel targets and optimized linker-payload combinations. The company is progressing three ADC programs: ADCE-T02 (Tissue Factor) in a Phase I Tiffany-01 cohort expansion across multiple solid tumors, ADCE-D01 (uPARAP) in Phase 1 dose escalation and expansion for soft tissue sarcoma and other mesenchymal cancers, and ADCE-B05 (undisclosed target) in preclinical evaluation and planned dose escalation in squamous cell carcinomas. Founded in 2017, Adcendo is headquartered in Copenhagen with operations in Boston, Massachusetts, and is led by a team with extensive ADC development and commercialization experience. The recent $75 million Series C financing is intended to fund the programs through upcoming clinical milestones and data readouts. No revenue or other operating metrics were disclosed in the provided articles.

Participated · Series C · Oct 2025

Hemab Therapeutics is focused on creating prophylactic, antibody-based treatments that address the underlying causes of serious bleeding disorders rather than just managing acute events. Its lead asset, sutacimig (formerly HMB-001), has completed Phase 2 in Glanzmann thrombasthenia and is being prepared for a registration study in 2026, with a parallel Phase 2 program planned for Factor VII deficiency. The company’s second clinical candidate, HMB-002, targets the C-terminal CK domain of Von Willebrand Factor to raise endogenous VWF and Factor VIII levels and is advancing toward registration studies in Von Willebrand disease. Backed by its “Hemab 1-2-5” strategy, the team is also moving additional programs forward, with HMB-003 expected to enter the clinic in the first half of 2026. Hemab’s dual headquarters in Cambridge, Massachusetts, and Copenhagen, Denmark, give it access to both U.S. and European scientific ecosystems. The fresh Series C financing provides $157 million to fund late-stage trials, expand the pipeline, and reinforce the company’s goal of becoming “the ultimate clotting company.”

Participated · Series A · Mar 2025

Tribune Therapeutics is advancing novel medicines to treat fibrosis regardless of cause, tissue, or diagnosis by targeting central, tissue‑agnostic drivers of scar formation in the CCN protein family. Its lead program, TRX‑44, is a CCN5 mimic designed to prevent scar formation by blocking the pro‑fibrotic effects of CTGF/CCN2 and WISP1/CCN4 across multiple cell types. The company’s approach aims to be broader than blocking individual CCN proteins or upstream activators like TGF‑beta, with the potential to avoid toxicities that have hindered less targeted strategies. Tribune is advancing multiple programs targeting CCN biology and plans to use new funding to prepare TRX‑44 to enter clinical trials for fibrotic indications including idiopathic pulmonary fibrosis (IPF). Tribune, based in Stockholm and Oslo, raised a total of €37 million in seed and Series A financings to support these programs. The financing and accompanying board additions are intended to advance the company’s preclinical programs toward the clinic. Tribune Therapeutics is a preclinical biopharmaceutical company founded in 2020 in Oslo developing medicines that exploit a novel pan-antifibrotic mechanism. The company in-licensed a breakthrough asset from Inven2 based on research from Håvard Attramadal’s lab. Its lead program targets fibrotic diseases affecting the kidney, lung and liver, and Tribune is building a pipeline across multiple fibrotic indications. Tribune was co-created and funded by HealthCap and Novo Seeds (the early-stage arm of Novo Holdings) and launched from stealth with seed financing. Leadership appointments associated with the launch include Executive Chairman Jonas Hansson, incoming CEO Georg Vo Beiske, and CSO Ole Jørgen Kaasbøll. The company is preclinical and no operating metrics or revenue figures are disclosed in the articles.

Participated · Equity · Mar 2025

HelloBetter offers ten online therapy programmes addressing depression, insomnia, panic disorders and underserved conditions such as vaginismus and chronic pain. Six programmes have BfArM approval and are fully integrated into Germany’s standard healthcare system as prescription digital therapeutics (DiGA), available free to publicly insured adults; 120,000 patients have used the programmes. The company has conducted 30 randomized controlled trials on its commercial products, most published in peer-reviewed journals, and in 2023 gained FDA approval for a digital therapeutic to treat panic disorders. Founded in 2015, HelloBetter operates across Berlin, Potsdam and Hamburg and employs over 150 professionals. The company launched HelloGina in the US in 2022 to address vaginismus and continues to develop new digital therapeutics. A priority for 2025 is entering the French market through pilots and partnerships with Mutuelles and pursuing regulatory approval by the HAS to secure nationwide reimbursement. HelloBetter provides ten online therapy programs addressing common conditions such as depression, insomnia, and panic disorders, as well as underserved conditions including vaginismus and chronic pain. Six of its programmes have been approved by the German Federal Institute for Drugs and Medical Devices (BfArM) and are integrated into Germany's standard healthcare system. Those approved programmes are available free of charge to publicly insured adults as prescription digital therapeutics. Earlier this year the company launched an AI product, MindFIT, in stealth mode and expects first results next year. HelloBetter has secured €3M in funding to develop and commercialise the AI to personalise user experience and improve adherence, satisfaction, and overall mental health outcomes. HelloBetter offers evidence-based digital therapy courses addressing stress, panic, depression, insomnia, and other mental health challenges. Founded in 2015, the company is a global pioneer in digital mental health research with 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of its ten therapy programs are part of the standard of care and are available free to publicly insured adults as prescription digital therapeutics (DiGA). The company expanded to the U.S. in 2022 under the HelloGina brand with a sexual wellness programme for vaginismus and received FDA 'breakthrough device' designation in early 2023. In 2023 HelloBetter has raised €12M to date, bringing total funding to €25M after a €5M second closing of its A2 round. The new capital will be used to invest in sales, marketing, and data analytics, enter new markets, and further expand its digital therapeutics portfolio. HelloBetter, founded in 2015 as Get.on and based in Hamburg, offers psychological online trainings aimed at the prevention and treatment of mental illnesses. Its core product line comprises digital therapeutics (DTx) delivered via online training programs. The company plans to use new capital to ramp up commercialisation of its DTx products in Germany. HelloBetter also aims to expand its presence across Europe and into the United States. The articles report that investors have now committed a total of around €20 million to the company. HelloBetter develops digital therapeutics (DTx) delivered as software-as-a-medical-device to prevent and treat mental and behavioral health conditions. The platform offers programs targeting burnout, depression in diabetes patients, chronic pain and vaginismus, and has secured universal health-insurance reimbursement for four products in Germany. The company reported a 125% increase in total clients treated from 2020 to 2021. HelloBetter works with health insurers and partners including Barmer, AudiBKK, Allianz, Swica and ratiopharm (a Teva subsidiary), plus over 100 employers. It has joined the Digital Therapeutics Alliance to support further international expansion. The company is focusing on commercialisation in the German market and advancing expansion beyond the DACH region.

Participated · Series B · Oct 2024

SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a monoclonal antibody that targets the CSF‑1 receptor to deplete tumor-associated macrophages in Tenosynovial Giant Cell Tumour (TGCT). The company has initiated the TANGENT Phase 3 trial — a global, multi-center, randomized, double-blind, placebo-controlled study planned for about 130 patients — and has dosed its first patients. Early clinical data reported an overall response rate (ORR) of approximately 71%. SynOx is also exploring emactuzumab’s potential in other macrophage-driven disorders, including graft‑versus‑host disease. The recent $92M Series B financing will support the Phase 3 program and further development. SynOx has raised $323.8M to date, was founded in 2020, and operates from Dublin with a presence in Oxford; the company reports 11–50 employees. SynOx Therapeutics is a late-stage clinical biopharmaceutical company developing emactuzumab, a monoclonal antibody that inhibits CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1–related and macrophage-driven diseases. The company is executing TANGENT, a registrational Phase 3 study of emactuzumab. Management, led by CEO Ray Barlow, aims to establish emactuzumab as a best-in-class drug to address unmet medical needs and improve patient quality of life. SynOx is headquartered in Dublin, Ireland and Oxford, UK. Financially, the company recently supplemented its balance sheet with a debt facility after completing a $75M Series B, positioning it to fund ongoing clinical development. The new financing is intended to support completion and advancement of the registrational program. SynOx Therapeutics is a clinical-stage biopharmaceutical spin-out from Celleron Therapeutics focused on developing emactuzumab, a humanized IgG1 CSF‑1R targeted antibody. Emactuzumab is designed to deplete tumour-associated macrophages and has shown a favorable safety profile and encouraging efficacy in diffuse tenosynovial giant cell tumours (TGCT). The company secured exclusive worldwide rights for the clinical development, manufacturing and commercialization of emactuzumab under a license agreement with Roche. SynOx announced a €37M Series A financing to fund continued development in TGCT and other indications. Management says it will focus on generating the data necessary to register the therapy in a time- and cost-efficient way. The team combines biotech and pharma experience and the board includes investor representatives alongside Celleron’s chairman and SynOx’s CEO.